Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Фаза 1
Завершено
NCT04520659
| Заболевание | RSV Infection |
|---|
| Фаза | Фаза 1 |
|---|
| Спонсор | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|
| Статус | Завершено |
|---|
| Участники | 81 участн. |
|---|
| Вмешательство | RSV LID/ΔM2-2/1030s |
|---|
| Дата начала | 16.03.2022 |
|---|
| Дата завершения | 18.04.2024 |
|---|
| Публикация результатов | 22.08.2025 |
|---|
Кратко
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine, LID/ΔM2-2/1030s, in RSV-seronegative infants and children 6 to 24 months of age.
Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 7 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 27 Participants |
|---|
| Group 2: Placebo | 11 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 41 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 18 Participants |
|---|
Frequency of Grade 2 or Higher Lower Respiratory Infections (LRI) by Grade
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 7 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 39 Participants |
|---|
| Group 2: Placebo | 17 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 53 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 24 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs) by Grade of Severity
Measured through Day 28 · Participants
| Group 1: RSV LID/ΔM2-2/1030s | 14 Participants |
|---|
| Group 1: Placebo | 6 Participants |
|---|
| Group 2: RSV LID/ΔM2-2/1030s | 29 Participants |
|---|
| Group 2: Placebo | 16 Participants |
|---|
| Groups 1 and 2 Combined: RSV LID/ΔM2-2/1030s | 43 Participants |
|---|
| Groups 1 and 2 Combined: Placebo | 22 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.